For an electric power grid that has large penetration levels of variable renewable energy including wind generation and photovoltaics, the system frequency stability is jeopardized, which is manifest in lowering frequency nadir and settling frequency. This paper suggests an enhanced primary frequency response strategy of a doubly-fed induction generator (DFIG) in association with pitch angle control. The DFIG works in de-loaded operation with a certain reserve power via pitch angle control prior to disturbances for frequency regulation. To address this, a function of the pitch angle is employed that decreases the pitch angle with time to slowly feed the active power to the power gird. The simulation results demonstrate the effectiveness and feasibility of the proposed primary frequency response strategy including the settling frequency and frequency nadir.

With the increasing penetration of renewable energy generation, the frequency stability of a power grid can be significantly threatened. A doubly-fed induction generator (DFIG) participates in the frequency support of a power grid by releasing kinetic energy (KE) to boost the frequency nadir (FN). However, during rotor speed restoration, it is difficult to counterbalance the size of a second frequency drop (SFD) and the rotor speed recovery duration. This paper proposes an improved torque limit-based inertial control (TLBIC) to raise the FN by releasing less kinetic energy while guaranteeing rapid frequency stabilization with reduced SFD. To this end, when detecting a disturbance, the DFIG enhances the active reference power to the torque limit, and then the active power reduces smoothly based on an exponential function until the maximum power point tracking (MPPT) curve is met, and the rotor speed reverts to the initialization operating condition along the MPPT curve. A simulation system model with various wind power penetrations is established in EMTP-RV. Results show that the proposed scheme boosts the FN at a high level with less KE and guarantees rapid frequency stabilization.

Power systems would face issues in system frequency stability when high scales of variable renewable energy generation are integrated in them. Battery energy storage systems (BESSs) with advanced control capability and rapid control response have become a countermeasure to solve the issues in system frequency stability. This research addresses a flexible synthetic inertial control strategy of the BESS to enhance the dynamic system frequency indices including the frequency nadir, settling frequency, and rate of change of the system frequency. To this end, the control loops based on the frequency excursion and rate of change of the system frequency are implemented into the d-axis controller of the BESS. The adaptive control coefficient of both control loops could be adjusted according to the instantaneous state of charge (SOC) so that it can inject more power to the grid at a higher SOC. The benefits of the proposed combined inertial control strategy are investigated with various sizes of disturbance and SOCs of the BESSs. Results successfully illustrate that the proposed combined inertial control strategy of the BESS is capable of enhancing the system frequency stability so as to promote variable renewable energy accommodation.

Triple-negative breast cancer (TNBC) accounts for 15–20% of all breast cancer cases. Due to the lack of expression of well-known molecular targets [estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)], there is a need for more alternative treatment approaches in TNBC. Chimeric antigen receptor (CAR)-T cell-based immunotherapy treatment is one of the latest treatment technologies with outstanding therapeutic advances in the past decade, especially in the treatment of hematologic malignancies, but the therapeutic effects of CAR-T cells against solid tumors have not yet shown significant clinical benefits. Identification of highly specific CAR-T targets in solid tumors is also crucial for its successful treatment. CD22 is reported to be a multifunctional receptor that is mainly expressed on the surface of mature B-cells (lymphocytes) and is also highly expressed in most B-cell malignancies. This study aimed to investigate the expression of CD22 in TNBC. Bioinformatic analysis was performed to evaluate the expression of CD22 in breast carcinoma and normal tissues. RNA-seq data of normal and breast carcinoma patients were downloaded from The Cancer Genome Atlas (TCGA), and differential gene expression was performed using R language. Additionally, online bioinformatics web tools (GEPIA and TNM plot) were used to evaluate the expression of CD22 in breast carcinoma and normal tissues. Western blot (WB) analysis and immunofluorescence (IF) were performed to characterize the expression of CD22 in TNBC cell lines. Immunohistochemical (IHC) staining was performed on tumor specimens from 97 TNBC patients for CD22 expression. Moreover, statistical analysis was performed to analyze the association of clinical pathological parameters with CD22 expression. Correlation analysis between overall survival data of TNBC patients and CD22 expression was also performed. Differential gene expression analysis of TCGA data revealed that CD22 is among the upregulated differentially expressed genes (DEGs) with high expression in breast cancer, as compared to normal breast tissues. WB and IF analysis revealed high expression of CD22 in TNBC cell lines. IHC results also showed that approximately 62.89% (61/97) of TNBC specimens were stained positive for CD22. Cell membrane expression of CD22 was evident in 23.71% (23/97) of TNBC specimens, and 39.18% (38/97) of TNBC specimens showed cytoplasmic/membrane expression, while 37.11% (36/97) specimens were negative for CD22. Furthermore, significant associations were found between the size of tumors in TNBC patients and CD22 expression, which unveils its potential as a prognostic biomarker. No significant correlation was found between the overall survival of TNBC patients and CD22 expression. In conclusion, we demonstrated for the first time that CD22 is highly expressed in TNBC. Based on our findings, we anticipated that CD22 could be used as a prognostic biomarker in TNBC, and it might be a potential CAR-T target in TNBC for whom few therapeutic options exist. However, more large-scale studies and clinical trials will ensure its potential usefulness as a CAR-T target in TNBC.